Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 7/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | LTB4R | Q15722 | 3/20 | 0.40 |
| ▸ | CCR2 | P41597 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8236990 | 0.93 | BACE1 (0.58) | BACE1MEN1KMT2ALTB4RCCR2 | |
| Trifluoroacetic Acid SCHEMBL4248393 | 0.88 | BACE1 (0.53) | BACE1MEN1KMT2AMAOAMAOB | |
| Trifluoroacetic Acid SCHEMBL4242602 | 0.83 | BACE1 (0.55) | BACE1MEN1KMT2ALTB4RALDH1A1 | |
| SCHEMBL13743980 | 0.82 | MEN1 (0.57) | BACE1MEN1KMT2ALTB4RCCR2 | |
| Trifluoroacetic Acid SCHEMBL4248535 | 0.78 | MEN1 (0.51) | BACE1MEN1KMT2ALTB4RPOLB | |
| SCHEMBL4252260 | 0.78 | BACE1 (0.62) | BACE1MEN1KMT2AMAOAMAOB | |
| Trifluoroacetic Acid SCHEMBL4242063 | 0.76 | KMT2A (0.49) | BACE1MEN1KMT2ALTB4RPOLB | |
| SCHEMBL8239238 | 0.75 | BACE1 (0.62) | BACE1MEN1KMT2ALTB4RALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL4250441 | 0.72 | BACE1 (0.57) | BACE1LTB4R | |
| Trifluoroacetic Acid SCHEMBL4243869 | 0.71 | BACE1 (0.42) | BACE1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215801-A9 | Novel 2-Aminopyrimidinone Derivatives And Their Use | ASTRAZENECA AB, SODERTAIJE, SWEDENASTEX THEREAPEUTICS LTD (GB) | 2009-08-27 | — | — | US | claimed |
| US-20080255164-A1 | Novel 2-Aminopyrimidinone Derivatives And Their Use | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | claimed |
| US-20090215801-A9 | Novel 2-Aminopyrimidinone Derivatives And Their Use | ASTRAZENECA AB, SODERTAIJE, SWEDENASTEX THEREAPEUTICS LTD (GB) | 2009-08-27 | — | — | US | disclosed |
| US-20080255164-A1 | Novel 2-Aminopyrimidinone Derivatives And Their Use | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
| EP-1951680-A1 | NOVEL 2-AMINOPYRIMIDINONE DERIVATIVES AND THEIR USE | Astra Zeneca AB (SE) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007058580-A1 | NOVEL 2-AMINOPYRIMIDINONE DERIVATIVES AND THEIR USE | ASTRAZENECA AB (SE) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215801-A9 | Novel 2-Aminopyrimidinone Derivatives And Their Use | PSEN2, PSEN1, MAPT | BACE1 9/4885MEN1 4103/4885KMT2A 2006/4885 |
| US-20080255164-A1 | Novel 2-Aminopyrimidinone Derivatives And Their Use | PSEN2, PSEN1, MAPT | BACE1 9/4885MEN1 4103/4885KMT2A 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.